Ligand Pharmaceuticals, Inc. (LGND)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
John L. Higgins
Employees:
150
3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA 92121
858-550-7500

Ligand Pharmaceuticals Incorporated focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae. The company also offers Rylaze, a recombinant erwinia asparaginase, and Nexterone, a captisol-enabled formulation of amiod

Data derived from most recent annual or quarterly report
Market Cap 1.228 Billion Shares Outstanding16.85 Million Avg 30-day Volume 204.751 Thousand
P/E Ratio80.0326 Dividend Yield0.0 EPS1.84
Price to Revenue7.0702 Debt to Equity0.2226 EBITDA129.328 Million
Price to Book Value2.386 Operating Margin24.236 Enterprise Value1.865 Billion
Current Ratio6.484 EPS Growth-0.421 Quick Ratio5.773
1 Yr BETA 1.3878 52-week High/Low 164.84 / 57.77 Profit Margin8.8342
Operating Cash Flow Growth147.9553 Altman Z-Score4.9239 Free Cash Flow to Firm 64.919 Million
Earnings Report2023-02-16
View SEC Filings from LGND instead.

View recent insider trading info

Funds Holding LGND (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LGND

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-04:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-03:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-30:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-02:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-06-29:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-21:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    11.7 Thousand total shares from 2 transactions

    Exercise Derivative Conversion (M)

    10 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    HIGGINS JOHN L CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    467,066 2022-11-17 12

    ESPINOZA OCTAVIO CHIEF FINANCIAL OFFICER

    • Officer
    8,857 2022-11-09 2

    FOEHR MATTHEW W

    • FORMER EXECUTIVE OFFICER
    162,187 2022-11-01 6

    BERKMAN CHARLES S

    • FORMER EXECUTIVE OFFICER
    23,825 2022-11-01 5

    PATEL SUNIL

    • FORMER DIRECTOR
    28,820 2022-11-01 2

    BOYCE SARAH

    • FORMER DIRECTOR
    2,892 2022-11-01 2

    KORENBERG MATTHEW E PRESIDENT & COO

    • Officer
    86,021 2022-11-01 6

    COCHRAN JENNIFER R.

    • FORMER DIRECTOR
    1,161 2022-11-01 2

    REARDON ANDREW SEE REMARKS

    • Officer
    12,013 2022-11-01 1

    HAAS JASON

    • Director
    0 2022-06-29 2

    LAMATTINA JOHN L

    • Director
    30,742 2022-06-10 1

    KOZARICH JOHN W

    • Director
    46,553 2022-06-10 2

    ARYEH JASON

    • Director
    130,627 2022-06-10 1

    DAVIS TODD C

    • Director
    56,126 2022-06-10 1

    SABBA STEPHEN L

    • Director
    33,674 2022-06-10 1

    GRAY NANCY RYAN

    • Director
    9,046 2022-06-10 1

    GOLDMAN SACHS GROUP INC

    GOLDMAN SACHS & CO. LLC

    686,330 2020-02-03 0

    HERMAN MELANIE J DIRECTOR OF ACCOUNTING

    • Officer
    3,454 2016-06-30 0

    KNOTT DAVID M

    • Director
    1,265,918 2015-08-17 0

    DESILVA NISHAN M VP, FINANCE & STRATEGY AND CFO

    • Officer
    22,282 2015-05-12 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BVF INVESTMENTS LLC

    BVF INC/IL

    LAMPERT MARK N

    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    No longer subject to file 2014-03-24 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BVF INVESTMENTS LLC

    INVESTMENT 10 LLC

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    6,978,580 2014-02-18 0

    SHARP JOHN P VP FINANCE AND CFO

    • Officer
    17,667 2014-02-12 0

    INVESTMENT 10 LLC

    • SEE EXPLANATION OF RESPONSES
    3,582,065 2013-01-01 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSES
    741,627 2012-10-26 0

    KAZMI SYED VP, BUS. DEV. & STRATEGIC PLAN

    • Officer
    18,230 2012-02-09 0

    MEGLASSON MARTIN V-P, DISCOVERY RESEARCH

    • Officer
    102,250 2010-05-11 0

    BURAKOFF STEVEN J

    • Director
    15,000 2009-05-29 0

    DZIEWANOWSKA ZOFIA E VP, CLINICAL RESEARCH

    • Officer
    33,977 2009-02-25 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BVF INVESTMENTS LLC

    BVF INC/IL

    • 10% Owner
    • INDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
    16,006,215 2009-01-23 0

    PEACOCK BRUCE

    • Director
    10,000 2008-12-23 0

    LIGAND PHARMACEUTICALS INC

    • Director
    10,000 2008-08-04 0

    GREETHAM ELIZABETH M

    • Director
    10,000 2008-05-29 0

    PERRY JEFFREY R

    • Director
    33,953 2008-05-29 0

    BLISSENBACH HENRY F

    • Director
    15,005 2007-04-02 0

    LOEB DANIEL S

    • FORMER DIRECTOR (1)
    2,027,378 2007-03-26 0

    DEMBITZ TERRY A VICE PRESIDENT, ADMINISTRATION

    • Officer
    262 2007-03-01 0

    GROVES ERIC S V-P, PROJECT MANAGEMENT

    • Officer
    5,127 2006-12-15 0

    PETTTIT WILLIAM A SR. V-P, HR AND ADMINISTRATION

    • Officer
    889 2006-12-15 0

    NEGRO-VILAR ANDRES EXE V-P, R & D, CSO

    • Officer
    42,233 2006-12-11 0

    BROADDUS WARNER R V-P, GEN. COUNSEL & SECY.

    • Officer
    20,104 2006-11-17 0

    MAIER PAUL V SR. V-P, CFO

    • Officer
    112,326 2006-11-17 0

    ROCCA MICHAEL A

    • Director
    10,000 2006-09-27 0

    CROSS ALEXANDER D

    • Director
    10,000 2006-09-27 0

    JOHNSON IRVING S

    • Director
    10,000 2006-09-27 0

    PECK CARL C

    • Director
    10,000 2006-09-27 0

    GROOM JOHN

    • Director
    10,000 2006-09-27 0

    LITALIEN JAMES J SR. V-P, REG AFFAIRS & COMP.

    • Officer
    20,000 2006-03-10 0

    ROBINSON DAVID E PRES, CEO & CHAIRMAN

    • Officer
    • Director
    50,000 2006-03-10 0

    CROUCH TAYLOR SR. V-P, OPS & PRES. INT'L

    • Officer
    20,000 2006-03-10 0

    MERTES TOD V-P, CONTROLLER & TREASURER

    • Officer
    20,000 2006-03-10 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    HIGGINS JOHN L - Director - Officer CHIEF EXECUTIVE OFFICER

    2022-11-21 19:04:42 -0500 2022-11-18 M 10,000 $12.78 a 426,731 direct -2.3107 -2.6312 0.0 1 -4.5412 5

    HIGGINS JOHN L - Director - Officer CHIEF EXECUTIVE OFFICER

    2022-11-21 19:04:42 -0500 2022-11-18 M 10,000 d 40,335 direct

    HIGGINS JOHN L - Director - Officer CHIEF EXECUTIVE OFFICER

    2022-11-21 19:04:42 -0500 2022-11-17 S 10,000 $78.32 d 416,731 direct yes -2.3107 -2.6312 0.0 1 -4.5412 5

    ESPINOZA OCTAVIO - Officer CHIEF FINANCIAL OFFICER

    2022-11-10 16:30:13 -0500 2022-11-09 S 1,696 $75.64 d 8,857 direct -1.9528 -4.9988 0.0 1 -4.9988 6

    HIGGINS JOHN L - Director - Officer CHIEF EXECUTIVE OFFICER

    2022-11-03 21:05:28 -0400 2022-11-01 A 45,922 a 424,731 direct 1.3548 31.3226 32.3226 5 0.0 1

    FOEHR MATTHEW W FORMER EXECUTIVE OFFICER

    2022-11-03 21:06:18 -0400 2022-11-01 D 20,304 d 162,187 direct 1.3548 31.3226 32.3226 5 0.0 1

    FOEHR MATTHEW W FORMER EXECUTIVE OFFICER

    2022-11-03 21:06:18 -0400 2022-11-01 D 34,214 d 0 direct

    BERKMAN CHARLES S FORMER EXECUTIVE OFFICER

    2022-11-03 21:06:31 -0400 2022-11-01 D 11,944 d 23,825 direct 1.3548 31.3226 32.3226 5 0.0 1

    BERKMAN CHARLES S FORMER EXECUTIVE OFFICER

    2022-11-03 21:06:31 -0400 2022-11-01 D 20,126 d 0 direct

    PATEL SUNIL FORMER DIRECTOR

    2022-11-03 21:06:59 -0400 2022-11-01 D 1,004 d 28,820 direct 1.3548 31.3226 32.3226 5 0.0 1

    PATEL SUNIL FORMER DIRECTOR

    2022-11-03 21:06:59 -0400 2022-11-01 D 4,340 d 0 direct

    BOYCE SARAH FORMER DIRECTOR

    2022-11-03 21:06:05 -0400 2022-11-01 D 1,004 d 2,892 direct 1.3548 31.3226 32.3226 5 0.0 1

    BOYCE SARAH FORMER DIRECTOR

    2022-11-03 21:06:05 -0400 2022-11-01 D 4,340 d 0 direct

    KORENBERG MATTHEW E - Officer PRESIDENT & COO

    2022-11-03 21:10:22 -0400 2022-11-01 A 27,714 a 86,021 direct 1.3548 31.3226 32.3226 5 0.0 1

    COCHRAN JENNIFER R. FORMER DIRECTOR

    2022-11-03 21:08:29 -0400 2022-11-01 D 1,004 d 1,161 direct 1.3548 31.3226 32.3226 5 0.0 1

    COCHRAN JENNIFER R. FORMER DIRECTOR

    2022-11-03 21:08:29 -0400 2022-11-01 D 4,340 d 0 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    LIGAND PHARMACEUTICALS LGND 2022-12-01 12:45:03 UTC 3.4163 0.4037 350000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 22:15:03 UTC 3.4163 0.4037 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 21:45:03 UTC 3.4317 0.3883 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 21:15:03 UTC 3.4317 0.3883 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 20:45:04 UTC 3.4416 0.3784 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 20:15:04 UTC 3.4416 0.3784 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 19:45:04 UTC 3.4416 0.3784 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 19:15:03 UTC 3.4416 0.3784 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 18:45:03 UTC 3.4416 0.3784 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 18:15:03 UTC 3.4416 0.3784 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 17:45:03 UTC 3.4416 0.3784 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 17:15:03 UTC 3.4416 0.3784 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 16:45:04 UTC 3.4166 0.4034 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 16:15:03 UTC 3.4166 0.4034 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 15:45:03 UTC 3.4166 0.4034 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 15:15:04 UTC 3.4166 0.4034 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 14:45:04 UTC 3.4166 0.4034 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 14:15:03 UTC 3.4166 0.4034 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 13:45:03 UTC 3.4119 0.4081 400000
    LIGAND PHARMACEUTICALS LGND 2022-11-30 13:15:03 UTC 3.4119 0.4081 400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund LGND -6.0 shares, $-436.32 2020-03-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund LGND -62.0 shares, $-4508.64 2020-03-31 N-PORT
    AQR Funds- AQR Large Cap Relaxed Constraint Equity Fund LGND -465.0 shares, $-46286.1 2019-09-30 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund LGND -43.0 shares, $-3126.96 2020-03-31 N-PORT
    UBS RELATIONSHIP FUNDS- UBS U.S. EQUITY ALPHA RELATIONSHIP FUND LGND -18048.0 shares, $-2018668.8 2020-06-30 N-PORT
    JNL Series Trust- JNL/AQR Large Cap Relaxed Constraint Equity Fund LGND -956.0 shares, $-145742.2 2021-03-31 N-PORT
    Morningstar Funds Trust- Morningstar Alternatives Fund LGND -138.0 shares, $-12700.14 2022-07-29 N-PORT
    Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund LGND -189.0 shares, $-17393.67 2022-07-31 N-PORT
    Guidestone Funds- Strategic Alternatives Fund LGND -79.0 shares, $-6802.69 2022-09-30 N-PORT
    AMERICAN BEACON FUNDS- American Beacon SSI Alternative Income Fund LGND -139.0 shares, $-11969.29 2022-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments